Search Results
Updates on anti-amyloid monoclonal antibodies for AD in Phase III trials
Why have anti-amyloid monoclonal antibodies performed differently in Phase III trials
Anti-amyloid combination strategies in Alzheimer's disease
Second generation of anti-amyloid monoclonal antibodies for Alzheimer's disease
Monoclonal Antibodies Targeting Amyloid for Alzheimer Disease
AD/PD™️ 2024 – Highlights research on earlier treatment with anti-amyloid immunotherapies
Experimental Alzheimer's drug shows benefits in phase 3 trial
Development of a new anti-amyloid antibody PMN310 for the treatment of Alzheimer’s disease
Topline donanemab results: most positive Phase III data to date
Phase III AHEAD 3-45 trial of lecanemab for preclinical Alzheimer’s disease
Important developments in dementia: biomarkers & clinical trials
Next-generation anti-amyloid therapies: prioritizing selectivity
